Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -3.02%22 Equity-to-Asset is 0.82 as of Jun. 2026, which is 2% above its 10-year median of 0.80. GuruFocus rates BJDX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 851 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 78.38% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bluejay Diagnostics Equity-to-Asset Related Terms
Bluejay Diagnostics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJDX vs VTAK, PFSA, RBOT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bluejay Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics (BJDX) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bluejay Diagnostics and its competitors. This is near median its historical median of 0.80. According to the industry distribution chart, Bluejay Diagnostics ranks #184 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 21.6%.
Is Bluejay Diagnostics' Equity-to-Asset too high?
Bluejay Diagnostics' current Equity-to-Asset of 0.82 is near median its 10-year median of 0.80. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Bluejay Diagnostics' value of 0.82 is 28.1% above this industry median. Based on the distribution chart, Bluejay Diagnostics ranks #184 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Equity-to-Asset compare to VTAK and PFSA?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #184 out of 851 companies for Equity-to-Asset. This places Bluejay Diagnostics in the top 22% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Bluejay Diagnostics' value of 0.82 is 28.1% above this benchmark. While the company's 10-year median is 0.80 vs. the industry median of 0.64, Bluejay Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluejay Diagnostics's current Equity-to-Asset of 0.82 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Equity-to-Asset of 0.82. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.80 and 28.1% above the Medical Devices & Instruments industry median of 0.64. Bluejay Diagnostics' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
22GF Score
Get the complete analysis for BJDX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
